Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion; To be eligible for inclusion, each patient must fulfill the following criteria:~* Patients must be between the ages of 18 and 80;~* Have been diagnosed with active rheumatoid arthritis according to ACR criteria;~* Have at least 6 swollen joints (max = 66) and 6 tender joints (max = 68) at screening and baseline visits;~* Patients must have at least one of the following:~* C-reactive protein \> 1.0 mg/dl at screening;~* erythrocyte sedimentation rate \> 20 mm/Hr;~* Morning stiffness \> 45 min. at screening;~* Patients must have blood test values per the following criteria:~* ALT, AST \< 1.2 U/l x ULN~* Albumin \> 2.5 g/dl~* Prothrombin Time \< 1.2 INR~* Hb \> 9.0 g/dl~* Hct \> 35%~* WBC \> 3000 μl (mm3)~* Neutrophils \> 1000 μl (mm3)~* Platelets \> 100000 μl~* Creatinine \< 1.2 mg/dl~* Patients must have voluntarily signed the informed consent~Exclusion; Patients are not eligible for this study if they fulfill one or more of the following criteria:~* Patients who received previous methotrexate therapy;~* Patients who received previous therapy with any biologic agent;~* Previous biologic therapy for a disease other than RA is permitted so long as their last dose was more than 120 days prior to baseline;~* Patients currently taking sulfasalazine;~* Previous sulfasalazine therapy is permitted so long as their last dose was more than 30 days prior to baseline;~* Patients currently taking hydroxychloroquine;~* Previous hydroxychloroquine is permitted so long as their last dose was more than 120 days prior to baseline;~* Female patients of child bearing potential who are pregnant or who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner;~* Male patients who are sexually active and not using two methods of contraception (at least one barrier: i.e. condom) with their partner;~* Patients with any current active infection or infections requiring IV drug therapy within 30 days of baseline or oral therapy within 15 days of Baseline;~* Patients that have had any surgical procedures within 30 days of baseline;~* Patients with a history of HIV, Hepatitis B or C;~* Patients who consume more than 7 units of alcohol per week (1 unit = 5 ounces/150 ml of wine = 1.5 ounces/45 ml spirits = 12 ounces/360 ml of beer);~* Patients currently receiving any investigational drug or have received an investigational drug within 30 days of baseline or 5 half-lives of the investigational drug (whichever is longer);~* Patients with a history of cancer within the past 5 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ;~* Patients with a history of, or any, disease associated with an inflammatory arthritis other than RA;~* Patients with a chest X-ray that indicates the presence of pulmonary fibrosis (Chest x-ray may be taken with in 28 days of screening);~* Patients receiving Probenecid;~* Patients who have received any steroid injections within 30 days of baseline;~* Patients with concomitant diseases that are unstable (i.e. cardiac, pulmonary) or that may affect drug activity (i.e. absorption, reactions, change in kinetics);~* Patients considered by the investigator to be an unsuitable candidate to receive CH-1504;~* Wheelchair or bed-bound patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 0.25 mg CH-1504 (Type: EXPERIMENTAL): 0.25 mg CH-1504
- 0.5 mg CH-1504 (Type: EXPERIMENTAL): 0.5 mg CH-1504
- 1.0 mg CH-1504 (Type: EXPERIMENTAL): 1.0 mg CH-1504
- Methotrexate (Type: ACTIVE_COMPARATOR): Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).